Moleculin Biotech, Inc. — 2017 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2017; this is an annual report, not a standalone fourth-quarter report. The company is a clinical-stage oncology drug developer with no approved products or product-sales revenue.
Business context and pipeline
Moleculin’s programs are based primarily on technology licensed from MD Anderson. Annamycin is its lead candidate for relapsed or refractory acute myeloid leukemia (AML); the FDA allowed its Phase I/II IND in September 2017 and granted it Orphan Drug designation. A U.S. site was preparing to treat an enrolled patient; Polish trial startup still required national authorization.
The FDA also allowed a physician-sponsored Phase I IND for WP1066 in recurrent malignant glioma and melanoma brain metastases. WP1220 was being prepared for a proof-of-concept trial in cutaneous T-cell lymphoma. WP1122 and other candidates remained preclinical. These programs are experimental; reported efficacy and safety observations are not evidence of established clinical benefit.
Financial results and liquidity
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $4.545 million | $1.496 million |
| General and administrative expense | $4.090 million | $2.381 million |
| Total operating expenses | $8.653 million | $3.883 million |
| Net loss | $9.805 million | $3.926 million |
| Basic and diluted loss per share | $0.53 | $0.40 |
| Net cash used in operations | $7.324 million | $3.765 million |
| Cash and cash equivalents at year-end | $7.714 million | $5.007 million |
Gross margin is not applicable because the company reported no revenue. Operating cash use increased with clinical preparation, research, staffing and related support costs. Financing provided $10.059 million in 2017, including stock issuance and warrant exercises. At year-end, current assets were $8.302 million and current liabilities were $2.215 million; total liabilities were $2.365 million. Convertible notes had been fully converted by June 2017. The balance sheet included $503,000 of warrant liability and $11.148 million of in-process research and development intangible assets.
In February 2018, the company sold 4.29 million shares and warrants for approximately $9.0 million gross, or approximately $8.27 million net. Management said year-end cash plus offering proceeds was expected to fund planned operations into the first quarter of 2019, subject to development and spending assumptions. The auditor’s report includes a going-concern paragraph stating that accumulated losses and lack of revenue raise substantial doubt about the company’s ability to continue as a going concern.
Material changes versus 2016
- R&D expense rose by approximately $3.0 million and G&A by approximately $1.7 million, reflecting increased development activity, personnel and professional costs.
- Net loss increased to $9.805 million from $3.926 million. The 2017 result included a $2.548 million noncash loss from remeasuring warrant liability, partly offset by a $1.238 million gain on warrant expirations and a $149,000 gain on liability settlement.
- Operating cash use rose by approximately $3.6 million; cash at year-end nevertheless increased, primarily due to equity financing and warrant exercises.
- The Annamycin IND was allowed after resubmission, and a physician-sponsored WP1066 IND was allowed. The company added a Phase I dose-ranging component to Annamycin’s plan, which it said would increase costs and add several months to potential development timing.
Outlook, risks, contingencies and unusual items
- Funding and going concern: The company expects continuing losses and needs additional capital to advance development. Funding may be unavailable or dilutive; management’s runway estimate does not cover product development through approval or commercialization.
- Clinical and regulatory uncertainty: Candidates remain at early stages, trials may be delayed or fail, and regulatory authorities may require additional work. Polish authorization for Annamycin remained pending. Prior Annamycin trials reported tumor lysis syndrome deaths; management planned prophylactic measures in future trials.
- Intellectual property: Annamycin’s composition-of-matter patent protection has expired; planned formulation, process and use patent applications may not be granted. The company relies on licensed rights and potential regulatory exclusivity.
- Licenses and related parties: The HPI arrangement requires $750,000 in quarterly payments over three years for access to development data, without obligating HPI to perform research. A $1.0 million buyout within three years of the May 2016 agreement would restore rights; otherwise HPI may convert its license to exclusive, potentially putting non-dermatology WP1066 rights at risk. The filing also describes historical related-party transactions that were not conducted at arm’s length.
- Operations and supply: The company depends on third-party manufacturers, CROs and research collaborators, has no manufacturing or commercial sales infrastructure, and disclosed limited suppliers for Annamycin API.
- Controls: Management concluded internal control over financial reporting was ineffective due to a material weakness in segregation of duties; disclosure controls were also ineffective. Remediation was underway, but completion was not assured. The auditor did not express an opinion on control effectiveness.
- Other items: The Tax Act’s deferred-tax remeasurement included a provisional $1.56 million expense offset by a full valuation allowance, with no net earnings impact. The company reported no current litigation. A new office lease was signed in March 2018, with estimated monthly base rent of approximately $4,300.
Important facts for investors to verify
- Actual Annamycin enrollment, dosing, safety and efficacy updates, including the status of Polish authorization and the planned response to tumor lysis risk.
- Whether the February 2018 financing and subsequent spending support the stated runway, and the timing and terms of any further financing or dilution.
- The status and financial consequences of the HPI buyout decision and continued access to WP1066 non-dermatology rights.
- Progress on patent applications, license obligations and any potential protection or exclusivity for Annamycin.
- Remediation of the segregation-of-duties material weakness and whether subsequent filings report effective controls.